
Jonathan D Plumb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6165375/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of Cells Expressing IL-17A and IL-17F in the Lungs of Patients With COPD. Chest, 2011, 139, 1089-1100.	0.4	105
2	Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. European Respiratory Journal, 2013, 42, 28-41.	3.1	88
3	The effect of peroxisome proliferator-activated receptor-Â ligands on in vitro and in vivo models of COPD. European Respiratory Journal, 2014, 43, 409-420.	3.1	85
4	Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax, 2011, 66, 489-495.	2.7	61
5	Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respiratory Research, 2014, 15, 103. Inhibition of Lipopolysaccharide-Stimulated Chronic Obstructive Pulmonary Disease Macrophage	1.4	53
6	Inflammatory Ġene Éxpression by Dexamethasone and the p38 Mitogen-Activated Protein Kinase Inhibitor <i>N</i> -cyano- <i>N</i> ′-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3	- <i>1.3 (i>d</i>])	Tj 21Qq0 0 (
7	Therapeutics, 2009, 328, 458-468. Reduced glucocorticoid receptor expression and function in airway neutrophils. International Immunopharmacology, 2012, 12, 26-33.	1.7	39
8	The effects of corticosteroids on COPD lung macrophages: a pooled analysis. Respiratory Research, 2015, 16, 98.	1.4	36
9	Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects. European Journal of Clinical Pharmacology, 2015, 71, 1175-1184.	0.8	36
10	Down Regulation of T Cell Receptor Expression in COPD Pulmonary CD8 Cells. PLoS ONE, 2013, 8, e71629.	1.1	34
11	Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients. Respiratory Research, 2016, 17, 124.	1.4	33
12	LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. International Immunopharmacology, 2012, 13, 225-231.	1.7	32
13	T lymphocyte insensitivity to corticosteroids in chronic obstructive pulmonary disease. Respiratory Research, 2012, 13, 20.	1.4	32
14	The role of the liver X receptor in chronic obstructive pulmonary disease. Respiratory Research, 2013, 14, 106.	1.4	29
15	P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells. Journal of Molecular Medicine, 2020, 98, 361-374.	1.7	25
16	Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells. Respiratory Research, 2016, 17, 9.	1.4	20
17	In Vitroandin SilicoTools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. Molecular Pharmaceutics, 2017, 14, 1033-1046.	2.3	20
18	COPD monocytes demonstrate impaired migratory ability. Respiratory Research, 2017, 18, 90.	1.4	19

JONATHAN D PLUMB

#	Article	IF	CITATIONS
19	Evaluation of Glucocorticoid Receptor Function in COPD Lung Macrophages Using Beclomethasone-17-Monopropionate. PLoS ONE, 2013, 8, e64257.	1.1	18
20	Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls. International Journal of COPD, 2016, Volume 11, 2139-2147.	0.9	14
21	CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in CD8 cells from COPD patients. Clinical Science, 2014, 126, 223-232.	1.8	12
22	Repeatability of induced sputum measurements in moderate to severe asthma. Respiratory Medicine, 2014, 108, 1566-1568.	1.3	11